Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Aroldi

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Recenti Progressi in Medicina|January 19, 2016
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]Francesca Aroldi, Alberto Zaniboni
Immunotherapy|June 10, 2017
Immunotherapy for pancreatic cancer: present and futureFrancesca Aroldi, Alberto Zaniboni
British Journal of Cancer|December 11, 2019
Window of opportunity clinical trial designs to study cancer metabolismFrancesca Aroldi, Simon R Lord
American Journal of Clinical Dermatology|April 1, 2022
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic MelanomaFrancesca Aroldi, Mark R Middleton
Recenti Progressi in Medicina|April 20, 2016
[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience]Francesca Aroldi, Chiara Ogliosi, Alberto Zaniboni
Reviews on Recent Clinical Trials|February 27, 2016
QT Prolongation and Anticancer Drugs: Is it a Cardiologist's Worry? The Oncologist's Point of ViewFrancesca Aroldi, Tiziana Prochilo, Elena Bonini, et al.
Journal of Chemotherapy (Florence, Italy)|August 7, 2014
Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and managementFrancesca Aroldi, Tiziana Prochilo, Paola Bertocchi, et al.
World Journal of Gastrointestinal Oncology|September 28, 2016
Pancreatic cancer: New hopes after first line treatmentFrancesca Aroldi, Paola Bertocchi, Giordano Savelli, et al.
Reviews on Recent Clinical Trials|October 1, 2015
Pancreatic Cancer: Promises and Failures of Target TherapiesFrancesca Aroldi, Paola Bertocchi, Edoardo Rosso, et al.
Journal of Chemotherapy (Florence, Italy)|December 30, 2016
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?Paola Bertocchi, Francesca Aroldi, Tiziana Prochilo, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Recenti Progressi in Medicina|January 19, 2016
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]Francesca Aroldi, Alberto Zaniboni
Immunotherapy|June 10, 2017
Immunotherapy for pancreatic cancer: present and futureFrancesca Aroldi, Alberto Zaniboni
British Journal of Cancer|December 11, 2019
Window of opportunity clinical trial designs to study cancer metabolismFrancesca Aroldi, Simon R Lord
American Journal of Clinical Dermatology|April 1, 2022
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic MelanomaFrancesca Aroldi, Mark R Middleton
Recenti Progressi in Medicina|April 20, 2016
[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience]Francesca Aroldi, Chiara Ogliosi, Alberto Zaniboni
Reviews on Recent Clinical Trials|February 27, 2016
QT Prolongation and Anticancer Drugs: Is it a Cardiologist's Worry? The Oncologist's Point of ViewFrancesca Aroldi, Tiziana Prochilo, Elena Bonini, et al.
Journal of Chemotherapy (Florence, Italy)|August 7, 2014
Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and managementFrancesca Aroldi, Tiziana Prochilo, Paola Bertocchi, et al.
World Journal of Gastrointestinal Oncology|September 28, 2016
Pancreatic cancer: New hopes after first line treatmentFrancesca Aroldi, Paola Bertocchi, Giordano Savelli, et al.
Reviews on Recent Clinical Trials|October 1, 2015
Pancreatic Cancer: Promises and Failures of Target TherapiesFrancesca Aroldi, Paola Bertocchi, Edoardo Rosso, et al.
Journal of Chemotherapy (Florence, Italy)|December 30, 2016
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?Paola Bertocchi, Francesca Aroldi, Tiziana Prochilo, et al.
Pageof 3